11/01/2019 21:30:00

InspireMD Receives Noncompliance Notice from NYSE American

TEL AVIV, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that on January 7, 2019, the Company received a letter from NYSE American LLC (“NYSE American”) stating that it is not in compliance with the continued listing standards as set forth in Part 10, Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) due to the Company’s current low selling share price.

The Company’s continued listing on the NYSE American is contingent upon the Company effecting a share consolidation or otherwise demonstrating a sustained improvement in its share price within a reasonable period of time but no later than July 7, 2019.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes.

InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at https://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

Craig Shore

Chief Financial Officer

InspireMD, Inc.

888-776-6804

craigs@inspiremd.com 

Jeremy Feffer

LifeSci Advisors, LLC

212-915-2568

jeremy@lifesciadvisors.com

inspiremd.png

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Mar
I:SP500
Hejsa Lidt forårs opdatering. Langsigtet konjunkturmodel: Nederst kan I se den langsigtede konjunktu..
63
18 Mar
GOMX
SAS's emmision overtegnet så de regner med 15MUSD i provenu samlet - godt nyt for GOMSpace hvis de k..
14
14 Mar
BA
Elliot.Blot for info så har jeg cirka 14.000 timer på 737 serien og der er altid problemer når en ty..
14
19 Mar
VELO
  Studiet er et randomiseret fase 4 forsøg, hvor man sammenligner forlænget frigivelse Envarsus XR (..
12
14 Mar
DANSKE
Danske Bank er sværd at værdiansætte set i forhold til den situation som Danske Bank befinder sig i...
12
13 Mar
ZEAL
Der er nogle enkelt punkter som jeg har noteret mig under læsningen af Årsrapporten 2018 samt de sen..
12
09:12
ZEAL
Jeg skrev til IR vedr. lidt forskelligt, her er deres svar:  Bliver der afholdt en Capital Market D..
11
18 Mar
BAVA
For mig virker det ret underligt at udmelding fra FDA om ydereligere 3mdr mere behandlingstid bliver..
11
15 Mar
PNDORA
Det forhold, at Pandora på trods af negativ analyse fra Carnegie og udbetaling af udbytte har holdt ..
11
19 Mar
FING-B
Siden topformationen i 23 området har trenden krydset flere støttelinjer og er nu ved en mulig dobbe..
10

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Health Insurance, Conagra, Kraft Heinz, and Diplomat and Encourages Investors to Contact the Firm
2
PDAC welcomes Federal Budget 2019
3
PureCircle Launches Next Generation Stevia Leaf Sweeteners in Singapore
4
NanoString Technologies Announces Pricing of Public Offering of 4,500,000 Shares of Common Stock
5
Dermira Prices $130.0 Million Public Offering of Common Stock

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 March 2019 20:07:48
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190320.1 - EUROWEB5 - 2019-03-20 21:07:48 - 2019-03-20 20:07:48 - 1000 - Website: OKAY